Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma

• Published in: Annals of oncology Vol. 16; no. 4; pp. 590 - 596
• Main Authors: Raspollini, M. R., Castiglione, F., Rossi Degl'Innocenti, D., Amunni, G., Villanucci, A., Garbini, F., Baroni, G., Taddei, G. L.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01-04-2005
• Subjects: Adult; Age Factors; Aged; alpha; beta T cell; CD3; CD3 Complex - immunology; Cystadenoma, Serous - immunology; Cystadenoma, Serous - pathology; Cystadenoma, Serous - therapy; delta T cell; Disease-Free Survival; Female; gamma; Humans; Lymphocytes, Tumor-Infiltrating - immunology; Middle Aged; ovarian carcinoma; Ovarian Neoplasms - immunology; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Receptors, Antigen, T-Cell, gamma-delta - biosynthesis; Retrospective Studies; T cells; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdi112

Background: Significant progress has been made in understanding the molecular biology of ovarian carcinoma. Along with the molecular characteristics of cancer, the patient's response to the tumour may also contribute to survival; in particular, the effect of the immune system may play an important role on survival of cancer patients. Patients and methods: We analysed the CD3 positive tumour-infiltrating T cells and direct molecular assessment of T cell receptors (TCRs) gamma and beta in 95 advanced ovarian carcinomas. Results: Gamma/delta T cells are statistically correlated with a brief disease-free interval (P=0.036). CD3 positive tumour-infiltrating T cells are correlated with a brief disease-free interval and with survival (P=0.004 and P=0.0001, respectively). CD3 positive tumour-infiltrating T cells are associated with clinical responsiveness to chemotherapy (P=0.003). Conclusions: Further studies are required to better understand the role of gamma/delta T cells in ovarian carcinoma, yet these data underline the importance of host immune response to cancer and the need to better study immune mechanisms to modulate the therapeutic treatment of cancer.